Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration.
Tamara Paulo TavaresDerek G V MitchellKristy Kl ColemanBrenda L ColemanChristen L ShoesmithChristopher R ButlerIsabel SantanaAdrian DanekAlexander GerhardAlexandre de MendoncaBarbara BorroniMaria Carmela TartagliaCaroline GraffDaniela GalimbertiFabrizio TagliaviniFermin MorenoGiovanni FrisoniJames Benedict RoweJohannes LevinJohn Cornelis van SwietenMarkus OttoMatthis SynofzikRaquel Sanchez-ValleRik VandenbergheRobert Jr LaforceRoberta GhidoniSandro SorbiSimon DucharmeMario MasellisJonathan RohrerElizabeth C Fingernull nullPublished in: Journal of neurology, neurosurgery, and psychiatry (2020)
Preclinical mutation carriers exhibited neuropsychiatric symptoms compared with non-carriers that may be considered as future clinical trial outcomes. Given the heterogeneity in symptoms, the detection of clinical transition to symptomatic FTD may be best captured by composite indices integrating the most common initial symptoms for each genetic group.